465 related articles for article (PubMed ID: 30926654)
1. Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study.
Cai Q; Zhu C; Yuan Y; Feng Q; Feng Y; Hao Y; Li J; Zhang K; Ye G; Ye L; Lv N; Zhang S; Liu C; Li M; Liu Q; Li R; Pan J; Yang X; Zhu X; Li Y; Lao B; Ling A; Chen H; Li X; Xu P; Zhou J; Liu B; Du Z; Du Y; Li Z;
Gut; 2019 Sep; 68(9):1576-1587. PubMed ID: 30926654
[TBL] [Abstract][Full Text] [Related]
2. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study.
Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Bostick RM; Wu X; Yuan Y
Am J Gastroenterol; 2017 May; 112(5):704-715. PubMed ID: 28323271
[TBL] [Abstract][Full Text] [Related]
3. The new modified ABCD method for gastric neoplasm screening.
Park CH; Kim EH; Jung DH; Chung H; Park JC; Shin SK; Lee SK; Lee YC
Gastric Cancer; 2016 Jan; 19(1):128-35. PubMed ID: 25663259
[TBL] [Abstract][Full Text] [Related]
4. Serological assessment of gastric intestinal metaplasia and atrophy using pepsinogen-I, pepsinogen-II and gastrin-17 levels in a low incidence area of gastric cancer endemic for H. pylori infection.
Ghoshal UC; Kumar S; Krishnani N; Kumari N; Chourasia D; Tripathi S
Trop Gastroenterol; 2011; 32(4):292-8. PubMed ID: 22696910
[TBL] [Abstract][Full Text] [Related]
5. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer.
Yoshida T; Kato J; Inoue I; Yoshimura N; Deguchi H; Mukoubayashi C; Oka M; Watanabe M; Enomoto S; Niwa T; Maekita T; Iguchi M; Tamai H; Utsunomiya H; Yamamichi N; Fujishiro M; Iwane M; Takeshita T; Ushijima T; Ichinose M
Int J Cancer; 2014 Mar; 134(6):1445-57. PubMed ID: 24009139
[TBL] [Abstract][Full Text] [Related]
6. Cutoff Pepsinogen Level for Predicting Unintendedly Eradicated Cases of Helicobacter pylori Infection in Subjects with Seemingly Normal Pepsinogen Levels.
Kishikawa H; Kimura K; Ito A; Arahata K; Takarabe S; Kaida S; Miyauchi J; Miura S; Kanai T; Nishida J
Digestion; 2017; 95(3):229-236. PubMed ID: 28355604
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of group D patients with negative serum anti-Helicobacter pylori antibody and positive serum pepsinogen test in healthy Koreans.
Han YM; Chung SJ; Choi JM; Lee C; Kim JS
J Dig Dis; 2018 Sep; 19(9):529-539. PubMed ID: 30117281
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of two serological methods in screening gastric cancer and its precancerous condition].
Li MY; Zhang DQ; Lu X; Chen WC
Zhonghua Nei Ke Za Zhi; 2018 Dec; 57(12):907-911. PubMed ID: 30486559
[No Abstract] [Full Text] [Related]
9. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study.
Tu H; Sun L; Dong X; Gong Y; Xu Q; Jing J; Long Q; Flanders WD; Bostick RM; Yuan Y
Int J Cancer; 2015 Jan; 136(2):425-34. PubMed ID: 24895149
[TBL] [Abstract][Full Text] [Related]
10. The correlation between histological gastritis staging- 'OLGA/OLGIM' and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China.
Wang X; Lu B; Meng L; Fan Y; Zhang S; Li M
Scand J Gastroenterol; 2017 Aug; 52(8):822-827. PubMed ID: 28436254
[TBL] [Abstract][Full Text] [Related]
11. Screening of precancerous gastric lesions by serum pepsinogen, gastrin-17, anti-helicobacter pylori and anti- CagA antibodies in dyspeptic patients over 50 years old in Guilan Province, north of Iran.
Mansour-Ghanaei F; Joukar F; Rajpout Y; Hasandokht T
Asian Pac J Cancer Prev; 2014; 15(18):7635-8. PubMed ID: 25292040
[TBL] [Abstract][Full Text] [Related]
12. Cancer/testis antigen, Kita-Kyushu lung cancer antigen-1 and ABCD stratification for diagnosing gastric cancers.
Shida A; Fukuyama T; Futawatari N; Ohmiya H; Ichiki Y; Yamashita T; Nishi Y; Kobayashi N; Yamazaki H; Watanabe M; Takahashi Y
World J Gastroenterol; 2020 Jan; 26(4):424-432. PubMed ID: 32063691
[TBL] [Abstract][Full Text] [Related]
13. Analysis of ABC (D) stratification for screening patients with gastric cancer.
Kudo T; Kakizaki S; Sohara N; Onozato Y; Okamura S; Inui Y; Mori M
World J Gastroenterol; 2011 Nov; 17(43):4793-8. PubMed ID: 22147980
[TBL] [Abstract][Full Text] [Related]
14. Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.
Watabe H; Mitsushima T; Yamaji Y; Okamoto M; Wada R; Kokubo T; Doi H; Yoshida H; Kawabe T; Omata M
Gut; 2005 Jun; 54(6):764-8. PubMed ID: 15888780
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer.
Pimanov SI; Makarenko EV; Voropaeva AV; Matveenko ME; Voropaev EV
J Gastroenterol Hepatol; 2008 Nov; 23(11):1666-71. PubMed ID: 17559360
[TBL] [Abstract][Full Text] [Related]
16.
MÄki M; SÖderstrÖm D; Paloheimo L; Hendolin P; Suovaniemi O; SyrjÄnen K
Anticancer Res; 2020 Nov; 40(11):6387-6398. PubMed ID: 33109577
[TBL] [Abstract][Full Text] [Related]
17. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study.
So JB; Yeoh KG; Moochala S; Chachlani N; Ho J; Wong WK; Mack P; Goh PM
Gastric Cancer; 2002; 5(4):228-32. PubMed ID: 12491081
[TBL] [Abstract][Full Text] [Related]
18. Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests.
Hamashima C; Sasazuki S; Inoue M; Tsugane S;
BMC Cancer; 2017 Mar; 17(1):183. PubMed ID: 28279154
[TBL] [Abstract][Full Text] [Related]
19. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study.
Gisbert JP; Boixeda D; Al-Mostafa A; Vila T; de Rafael L; Alvarez Baleriola I; de Argila CM; Abraira V
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):189-200. PubMed ID: 10102232
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer.
Wang Y; Zhu Z; Liu Z; Zhao Z; Xue X; Li X; Li P; Rong G; Ma Y
J Int Med Res; 2020 Mar; 48(3):300060520914826. PubMed ID: 32228342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
